Who are Pirfenidone Oral Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pirfenidone or nintedanib, Pirfenidone Capsules, COL-1620, pirfenidone 8% gel, Triamcinolone + Pirfenidone, Topical Pirfenidone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pirfenidone-oral-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Pirfenidone Oral Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pirfenidone Oral Product (Pirfenidone Oral Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrotic. Area: Pulmonology.

phase 3 Antifibrotic TGF-β receptor Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Pirfenidone Oral Product (Pirfenidone Oral Product) — Capital Medical University. Pirfenidone is an antifibrotic agent that inhibits the production of transforming growth factor-beta (TGF-β), a key cytokine involved in fibrosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pirfenidone Oral Product TARGET	Pirfenidone Oral Product	Capital Medical University	phase 3	Antifibrotic	TGF-β receptor
pirfenidone or nintedanib	pirfenidone or nintedanib	Hospices Civils de Lyon	marketed	Antifibrotic agent	Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases
Pirfenidone Capsules	Pirfenidone Capsules	Shanghai Zhongshan Hospital	marketed	Antifibrotic agent	TGF-β pathway; multiple pro-fibrotic cytokines
COL-1620	COL-1620	Merck KGaA, Darmstadt, Germany	phase 3	Antifibrotic agent
pirfenidone 8% gel	pirfenidone 8% gel	Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.	phase 3	Antifibrotic agent	TGF-β signaling pathway; fibroblast proliferation
Triamcinolone + Pirfenidone	Triamcinolone + Pirfenidone	Centro Dermatológico Dr. Ladislao de la Pascua	phase 3	Corticosteroid and antifibrotic
Topical Pirfenidone	Topical Pirfenidone	Centro Dermatológico Dr. Ladislao de la Pascua	phase 3	Antifibrotic	TGF-β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrotic class)

Beijing Continent Pharmaceutical Co, Ltd. · 1 drug in this class
Capital Medical University · 1 drug in this class
Centro Dermatológico Dr. Ladislao de la Pascua · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pirfenidone Oral Product — Competitive Intelligence Brief. https://druglandscape.com/ci/pirfenidone-oral-product. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab